Tokyo, July 22 (Jiji Press)--The Japanese Central Social Insurance Medical Council, which advises the health minister, on Wednesday approved the application of public health insurance to RiHeart, a cardiac muscle cell sheet that uses induced pluripotent stem, or iPS, cells,

Tokyo, July 21 (Jiji Press)--Long-term safety has been confirmed after neural progenitor cells derived from induced pluripotent stem, or iPS, cells, were transplanted into…

iPS細胞からつくった心不全治療の再生医療製品「リハート」が9月1日から、公的医療保険の対象となることが決まった。価格は5320万円。厚生労働省が22日の中央社会保険医療協議会(厚労相の諮問機関)で…